Caitrin W McDonough

About

Dr. Caitrin W McDonough is an assistant professor in the Department of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy. She holds a B.S. in Biochemistry with a minor in chemistry from the University of Iowa, a Ph.D. in Molecular Medicine and Translational Science from Wake Forest University School of Medicine, and an M.S. in Biomedical Informatics from the University of Florida. Her postdoctoral fellowship was completed at the University of Florida in Cardiovascular Pharmacogenomics under the guidance of Dr. Julie Johnson. Her research focuses on identifying and predicting patients at high risk for cardiovascular disease. She employs multiple methods, including regression modeling and machine learning, to analyze data from various sources such as electronic health records, insurance claims, and ‘omics data. Her work aims to identify factors or signatures associated with adverse cardiovascular outcomes and drug response. Dr. McDonough is involved in NIH-funded projects utilizing data from the All of Us research program to study treatment-resistant hypertension, adverse cardiovascular outcomes after P2Y12 inhibitor treatment, and adverse outcomes with statin therapy. She is also a co-leader of the International Consortium for Antihypertensive Pharmacogenomic Studies, collaborating globally to advance the field of antihypertensive pharmacogenomics.

Research topics

• Medicine
• Internal medicine
• Biology
• Genetics
• Cardiology
• Bioinformatics
• Immunology

Selected publications

• Stroke genetics informs drug discovery and risk prediction across ancestries

  Nature · 2022 · 586 citations

  . Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.

  DOI

• Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality

  European Heart Journal · 2021 · 91 citations

  AIMS: Inflammation plays an important role in cardiovascular disease (CVD) development. The NOD-like receptor protein-3 (NLRP3) inflammasome contributes to the development of atherosclerosis in animal models. Components of the NLRP3 inflammasome pathway such as interleukin-1β can therapeutically be targeted. Associations of genetically determined inflammasome-mediated systemic inflammation with CVD and mortality in humans are unknown. METHODS AND RESULTS: We explored the association of genetic N…

  DOI

• SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw

  Journal of Bone and Mineral Research · 2020 · 24 citations

  > 0.8) with rs7896005. To validate the association between these SNPs and MRONJ, we genotyped these three SNPs on the germline DNA from 104 cancer patients of European ancestry treated with iv BPs (46 cases and 58 controls). Multivariable logistic regression analysis showed the minor alleles of these three SNPs were associated with lower odds for MRONJ. The odds ratios (95% confidence interval) and p values were 0.351 (0.164-0.751; p = 0.007) for rs3758391, 0.351 (0.164-0.751; p = 0.007) for rs9…

  DOI

• Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score

  Journal of the American College of Cardiology · 2024 · 23 citations

  PublisherOA PDFDOI

• Impact of the ABCD‐GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi‐Site, Real‐World Investigation

  Clinical Pharmacology & Therapeutics · 2022 · 23 citations

  The Age, Body mass index, Chronic kidney disease, Diabetes mellitus, and CYP2C19 GENEtic variants (ABCD-GENE) score was developed to identify patients at risk for diminished antiplatelet effects with clopidogrel after percutaneous coronary intervention (PCI). The objective of this study was to validate the ability of the ABCD-GENE score to predict the risk for atherothrombotic events in a diverse, real-world population of clopidogrel-treated patients who underwent PCI and received clinical CYP2C…

  PublisherOA PDFDOI

Recent grants

• Hypertension Prediction and Identification in All of Us

  NIH · $305k · 2023–2025

• INTEGRATIVE DATA APPROACHES FOR RESISTANT HYPERTENSION IDENTIFICATION AND PREDICTION

  NIH · $486k · 2018–2022

• NIH Grant F31MH069136

  NIH · $63k · 2006

Frequent coauthors

• Julie A. Johnson

  University of North Carolina at Chapel Hill

  335 shared

• Yan Gong

  University of Florida

  316 shared

• Rhonda M. Cooper‐DeHoff

  University of Florida

  270 shared

• John G. Gums

  University of Florida

  232 shared

• Eric Boerwinkle

  The University of Texas Health Science Center at Houston

  225 shared

• Stephen T. Turner

  Australian Regenerative Medicine Institute

  213 shared

• Amber L. Beitelshees

  University of Maryland, Baltimore

  166 shared

• Kent R. Bailey

  Mayo Clinic

  141 shared

Education

• B.S., Biochemistry (with a minor in chemistry)

  University of Iowa

• Ph.D., Molecular Medicine and Translational Science

  Wake Forest University School of Medicine

Similar researchers at University of Florida

• Charles Peloquinh-84
• Joseph Collinsh-61